Mottiwala Aziz 4

What Happened

Mottiwala Aziz, Chief Commercial Officer of Tarsus Pharmaceuticals (TARS), sold a total of 13,056 shares in three open-market transactions between March 17–19, 2026, generating approximately $892,528 in proceeds. The individual sales were: 4,286 shares at $69.42 for $297,534 (3/17), 4,330 shares at $68.71 for $297,514 (3/18), and 4,440 shares at $67.00 for $297,480 (3/19). These were sales (not purchases) and are reported as routine.

Key Details

• Transaction dates and prices:
  • 2026-03-17: 4,286 shares @ $69.42 = $297,534
  • 2026-03-18: 4,330 shares @ $68.71 = $297,514
  • 2026-03-19: 4,440 shares @ $67.00 = $297,480
• Total shares sold: 13,056; total proceeds: ≈ $892,528.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The sales were "sell-to-cover" transactions required by the issuer to satisfy tax withholding on vested Restricted Stock Units (RSUs); this was not a discretionary sell by the reporting person (Footnote F1).
• Filing: Form 4 filed 2026-03-19 (covers transactions from 3/17–3/19); filing appears timely.

Context

These sales were mandated to cover tax withholding obligations tied to RSU vesting, which is a common administrative transaction and does not necessarily signal insider sentiment about the company. For retail investors, purchases are often more informative about insider confidence; required "sell-to-cover" transactions are routine.